The CYPRESS study missed its primary endpoint, but post-hoc analyses and a forthcoming FDA Type C meeting provide a potential, albeit uncertain, path forward for ampreloxetine. The stock's reaction will likely hinge on the outcome of the Type C meeting and the progress of the Zymeworks merger. Monitor for updates on the Type C meeting and any definitive proxy statement filings regarding the merger.
Price Chart
Executive Summary
Theravance Biopharma filed a DEFA14A (additional definitive proxy soliciting material) on August 25, 2026, making available a presentation on the Phase 3 CYPRESS study of ampreloxetine for symptomatic neurogenic orthostatic hypotension (nOH) associated with multiple system atrophy (MSA). The study missed its primary endpoint, but post-hoc analyses suggest a potential treatment effect, and the FDA has granted a Type C meeting to discuss a future study design. This filing is part of ongoing solicitation materials related to the proposed merger with Zymeworks Inc., previously announced on June 29, 2026.
Key Facts
- The primary endpoint of the Phase 3 CYPRESS study (change in OHSA composite score at week 8) was not statistically significant.
- Post-hoc analyses in a 'Confirmed Symptomatic nOH' population showed statistically significant average treatment effects for OHSA, OHDAS, and OHQ scores.
- The FDA has granted a Type C meeting request to align on the design of a future clinical study for ampreloxetine.
- The filing is a DEFA14A, which is additional definitive proxy soliciting material related to the proposed merger with Zymeworks Inc., announced June 29, 2026.
- The presentation includes data showing ampreloxetine was generally well tolerated with no signal of worsening supine hypertension.
Financial Impact
No financial figures reported in the filing. The filing relates to clinical data and regulatory interactions for ampreloxetine, and a proposed merger with Zymeworks Inc.
Risk Factors
- The primary endpoint of the CYPRESS study was not met, indicating a failed trial.
- Post-hoc analyses may not be replicated or predict clinical benefit in a future trial.
- The FDA may reject a proposed study design or require additional trials, delaying or preventing approval.
- The proposed merger with Zymeworks Inc. is subject to shareholder approval and other conditions, which may not be satisfied.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001104659-26-100863 |
| Document: 0001104659-26-100863-index.html | 0001104659-26-100863 |
| Document: 0001104659-26-100863.txt | 0001104659-26-100863 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 25, 2026 5w ago | DEFA14A | $17.03 $17.03 | · 0.00% | ▼ −0.23% | — |
Aug 21, 2026 6w ago | DEFM14A | $17.01 $17.05 | ▲ +0.24% | ▲ +0.76% | — |
Aug 11, 2026 7w ago | PREM14A | $16.91 $17.06 | ▲ +0.89% | ▲ +1.95% | — |
Aug 10, 2026 7w ago | 8-K | $16.91 $17.06 | ▲ +0.89% | ▲ +1.80% | — |
Jun 29, 2026 13w ago | 8-K | $17.06 $16.86 | ▼ −1.17% | ▼ −0.89% | — |
Jun 23, 2026 14w ago | 8-K | $17.27 $16.81 | ▼ −2.66% | ▼ −4.60% | — |
May 7, 2026 21w ago | 8-K | $17.02 $15.92 | ▼ −6.46% | ▼ −9.60% | — |
Mar 3, 2026 30w ago | 8-K | $13.96 $16.23 | ▼ −16.26% | ▼ −20.66% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access